Abstract

Diffuse histiocytic lymphoma (DHL), the paradigm of the aggressive lymphomas, is the most common subtype among the non-Hodgkin’s lymphomas. Current therapeutic strategies are based on a long history of clinical trials. Radiation therapy has repeatedly proved insufficient to control high grade lymphomas [1, 2]. DHL is very sensitive to chemotherapy as even single agent treatment may produce complete remission (CR) [3]. Early drug combinations yielded CR rates as high as 44%, but median relapse-free survival was approximately 14 months [4]. Others reported CR rates of 15 to 20% and also found short relapse-free survival [5].

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.